To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: Final overall survival results of MONARCH 3’ by M. P. Goetz et al.
-
Published:2024-08
Issue:8
Volume:35
Page:748-749
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Orlandi A.ORCID,
Mastrantoni L.ORCID,
Bria E.,
Tortora G.